Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 81 | ECE2022 | Next issue

European Congress of Endocrinology 2022

Milan, Italy
21 May 2022 - 24 May 2022

Card image cap
The 24th European Congress of Endocrinology (ECE) and the Italian Society of Endocrinology look forward to welcoming you to Milan. ECE 2022 returns for a four day, six parallel session festival of endocrine science. You can join us In person in Milan, Italy OR Live @Home online!

Rapid Communications

Rapid Communications 7: Pituitary and Neuroendocrinology 2

ea0081rc7.1 | Rapid Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Does the postoperative dose of hydrocortisone influence the health-related quality of life in patients with cured Cushing syndrome?

Kraljevic Ivana , Barac Anja , Solak Mirsala , Skoric Polovina Tanja , Balasko Annemarie , Zibar Tomsic Karin , Dusek Tina , Kastelan Darko

Objective: Patients with Cushing syndrome (CS) have impaired health-related quality of life (HRQoL) before and after surgery. The data on the optimal hydrocortisone dose after surgical cure of CS is scarce. Therefore, we investigated the influence of hydrocortisone dose on HRQoL after surgical treatment of CS. We hypothesized that patients who receive higher hydrocortisone doses after surgery would have better HRQoL and fewer cortisol withdrawal symptoms.<p class="abstext"...

ea0081rc7.2 | Rapid Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Development and internal validation of a predictive score for the diagnosis of central adrenal insufficiency when morning cortisol is in the grey zone

Bioletto Fabio , Maria Berton Alessandro , Varaldo Emanuele , Cuboni Daniela , Bona Chiara , Parasiliti Caprino Mirko , Prencipe Nunzia , Ghigo Ezio , Grottoli Silvia , Maccario Mauro , Gasco Valentina

Background: When evaluating a patient for central adrenal insufficiency (CAI), there is a wide range of morning cortisol values for which no final conclusion on hypothalamus-pituitary-adrenal (HPA) axis function can be drawn; in these cases, a stimulation test is required. Aim of this study was to develop an integrated model for the prediction of CAI when morning cortisol is in the grey zone, here defined as 40.0-160.0 μg/l.Methods: Overall, 119 pat...

ea0081rc7.3 | Rapid Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Pituitary microadenoma vs macroadenomas in cushing’s disease: does size matter?

Akirov Amit , Shimon Ilan , Yosi Manisterski , Aviran-Barak Nirit , Nadler Varda , Alboim Sandra , Kopel Vered , Tsvetov Gloria , Hirsch Dania

Background: The majority of adrenocorticotropic hormone (ACTH)-secreting pituitary adenomas are less than 10 mm in diameter and are described as microadenomas, while corticotroph macroadenomas (≥10 mm) are a less common cause of Cushing’s disease. Prior reports on the differences of clinical and biochemical behavior of corticotroph microadenomas and macroadenomas were inconsistent.Objective: Describe the clinical and biochemical characteristic...

ea0081rc7.4 | Rapid Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Evaluation of the impact of covid-19 on the hypothalamic-pituitary-adrenal axis and the hypothalamic-pituitary-thyroid axis

Andre Juliette , Al-Salameh Abdallah , Scherman Noemie , Andrejak Claire , Desailloud Rachel

Context: The long-term consequences of Covid-19 are unknown. Most patients experience persistent symptoms more than a month after the acute illness, including fatigue, dyspnea, memory loss, concentration disorder. The pituitary, the thyroid and the adrenal gland express the ACE-2 receptor, which is the cellular receptor for SARS-CoV-2, and could therefore be affected by the virus. However, the effect of Covid-19 on the hypothalamic-pituitary-adrenal-axis and hypothalamic-pitui...

ea0081rc7.5 | Rapid Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Osilodrostat therapy improves physical manifestations of hypercortisolism in patients with cushing’s disease: findings from the phase III LINC 3 study

Pivonello Rosario , Fleseriu Maria , Akira Shimatsu , Newell-Price John , Auchus Richard , Feelders Richard , Pedroncelli Alberto , Piacentini Andrea , Biller Beverly MK

Background: Improving physical manifestations of hypercortisolism is an important treatment goal for patients with Cushing’s disease (CD). In the Phase III LINC 3 study (NCT02180217), osilodrostat therapy, a potent oral 11β-hydroxylase inhibitor, rapidly normalised mean urinary free cortisol (mUFC) in most patients with CD and sustained control of mUFC over a median treatment period of 130 weeks (W). Here we describe concomitant improvements in physical manifestation...

ea0081rc7.6 | Rapid Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Long-term results from the Phase III LINC 4 study: Osilodrostat maintained normal mean urinary free cortisol in patients with Cushing’s disease, with a favourable safety profile

Gadelha Monica , Snyder Peter J , Witek Przemysław , Bex Marie , Belaya Zhanna , Turcu Adina F , Feelders Richard , Heaney Anthony , Paul Michaela , Pedroncelli Alberto , Auchus Richard

Background: Osilodrostat (potent oral 11β-hydroxylase inhibitor) provided rapid normalisation of mean urinary free cortisol (mUFC) in Cushing’s disease (CD) patients during the 48-week (W) core period of LINC 4 (NCT02697734) and was well tolerated. We report long-term efficacy and safety results from the LINC 4 core and extension phases.Methods: 73 adults with CD and mUFC >1.3 upper limit of normal (ULN) were enrolled. LINC 4 comprised a 12...

ea0081rc7.7 | Rapid Communications 7: Pituitary and Neuroendocrinology 2 | ECE2022

Outcome in repeat transsphenoidal surgery in patients with persistent and recurrent Cushing’s disease

Nasi-Kordhishti Isabella , Honegger Jurgen

Objective: Transsphenoidal surgery is the treatment of choice for Cushing’s disease (CD). Surgery is challenging due to the often very small adenomas. In experienced pituitary centers a high remission rate is reported. Nevertheless, endocrinologists and neurosurgeons face cases with persistent or recurrent CD. These patients must be referred to an experienced pituitary center. In addition to medical treatment, radiation therapy and bilateral adrenalectomy, repeat TSS must...